LIST OF TABLES

Table No	Content	Page No
4.1	List of drugs and suppliers	102
4.2	List of chemicals and suppliers	102
4.3	List of excipients used in formulation	103
4.4	List of equipment	104
4.5	Compatibility studies	124
4.6	Preparation of Loratadine orally disintegrating tablets	126
4.7	Drug Excipient compatibility studies	132
4.8	Formulation of chewable tablet (composition)	133
4.9	Scale of Flow ability	137
4.10	Flow properties and corresponding angle of repose	138
4.11	Weight variation	139
4.12	Loratadine immediate release layer	144
4.13	Flow properties corresponding to compressibility index as per USP31- NF26	147
4.14	Specifications of Hausner's ratio	147
4.15	Phenylephrine HCl sustained release layer	149
4.16	Flow properties corresponding to compressibility index as per USP31- NF26	152
4.17	Specifications of Hausner's ratio	153
5.1	Drug excipient compatibility studies	157
5.2	Formulation of loratadine ODT tablet	162
5.3	Evaluation of tablets	164
5.4	Percentage of cumulative drug release of all formulations	165

5.5	Stability studies of Loratadine orally disintegrating tablets 10mg	167
5.6	Drug excipient compatibility studies	169
5.7	Formulation of chewable tablet (composition)	174
5.8	Blend characterization for the formulation (T1-T6) of loratadine chewable tablet	176
5.9	Evaluation of loratadine chewable tablets	177
5.10	Content uniformity of the tablets	178
5.11	Percentage cumulative drug release of all formulations	179
5.12	Stability studies of Loratadine chewable tablets 5mg	180
5.13	Standard curve for Loratadine (Conc Vs Abs)	189
5.14	Standard curve for phenylephrine HCl (Conc Vs Abs)	190
5.15	Formulation of loratadine immediate release layer	192
5.16	Formulation of phenylephrine HCl sustained release layer	192
5.17	Powder flow properties of the Loratadine blend	194
5.18	Loratadine powder particle size distribution	194
5.19	Powder flow properties of the phenylephrine HCl blend	196
5.20	Phenylephrine HCl powder particle size distribution	196
5.21	The physical properties of loratadine and phenyl ephedrine bilayer tablet	197
5.22	Loratadine release profile	198
5.23	Phenylephrine HCl drug release profile	200
5.24	Stability studies of Loratadine and phenylephrine HCl tablets	202

LIST OF FIGURES

Figure No.	Contents	Page No.
5.1	DSC Thermograms of Loratadine with major excipients for ODTs	157
5.2	Absorbance values for standard calibration curve in SGF without enzyme	161
5.3	Comparative dissolution profiles of three different diluents used in formulation	166
5.4	Formulation of orally dispersible tablets of Loratadine	167
5.5	DSC Thermograms of Loratadine with major excipients for chewable tablets	169
5.6	Absorbance values for standard calibration curve in SGF without enzyme	173
5.7	Percentage cumulative drug release of all formulations	179
5.8	Chewable tablets of Loratadine	180
5.9	DSC Thermograms of Loratadine and phenylephrine with major excipients for bilayer tablets	182
5.10	Standard curve for Loratadine	189
5.11	Standard curve for phenylephrine HCl	190
5.12	*In vitro* percentage drug release Vs time profile of Loratadine IR layer	199
5.13	*In vitro* percentage drug release Vs time of phenylephrine HCl SR layer	200
5.14	Loratadine and Phenylephrine HCl extended release bilayer tablets	203